DIGITAL HEALTHCARE

Nemaura Medical Launches Metabolic Health Program for Employers and Insurers

Nemaura Medical, Inc | January 14, 2022

Nemaura Medical, Inc. (“Nemaura” or the “Company”), a medical technology company focused on developing and commercializing non-invasive wearable diagnostic devices and supporting personalized lifestyle coaching programs, announces the launch for employers and insurers of Miboko, a new metabolic health program using a non-invasive glucose sensor along with an AI mobile application. The Company’s goal is to achieve broad adoption of Miboko as a form of preventative medicine for a wide user base through these commercial channels and is aligned with the general trend in consumer digital healthcare.

“Introducing Miboko to the population at-large through employers and insurers will allow Nemaura to reach a much wider audience in much faster fashion than solely relying on a direct-to-consumer campaign, and in the Western world, these institutions are the most reliable gateway toward wider adoption of preventative health maintenance practices. Being aware of one’s metabolic health and how the body uniquely regulates sugar is key to one’s health. Patients, of course, want to be as informed as possible about their health, and employers and insurers are also aligned with patients in that regard, given the massive productivity losses and healthcare costs at stake on a larger scale across their employee and insured base, respectively. Miboko can help address this substantial market opportunity through our non-invasive, revolutionary approach to healthcare.”

Nemaura CEO Dr. Faz Chowdhury

Nemaura has also submitted a Premarket Approval (PMA) to the United States Food and Drug Administration (FDA) for approval of its glucose monitoring device as a Class 3 medical device. The Company’s PMA was the subject an on-site FDA bioresearch monitoring (BIMO) audit that generated a single Form 483 observation, for which the Company has committed to a full response this quarter. A follow-up BIMO audit of the clinical investigator site has also been scheduled for the current financial quarter.

Miboko has been in development for nearly two years and addresses a significant mass market opportunity that the Company believes could benefit roughly a third to half of the population by using a non-invasive glucose sensor to measure and monitor a user’s metabolic health score, which is based on glucose tolerance or insulin resistance. Those with prediabetes or obesity concerns -- or even those looking to maintain better health through more careful glucose control -- may benefit from such a metabolic health program. How one’s body metabolizes sugar is the main influencer of one’s appetite, weight, sleep quality, and energy and mood levels and even plays a critical factor in chronic diseases (beyond just diabetes), such as heart disease and dementia.

At the heart of the Miboko offering is Nemaura’s non-invasive glucose sensor that is designed to measure insulin resistance, reported as a metabolic health score, and priced to be highly affordable with the program running for an initial two-year period. The program also uses a mobile app to provide users with personalized information by tracking their metabolism. A user can find out how well their body responds to sugar through their metabolic health score — and how what they eat and what they do every day uniquely affects their metabolic health.

Along with the capability to follow metabolic health progress on the app, Miboko users receive weekly and monthly reports that show and explain their body’s unique metabolic health score and a breakdown of how each of their habits are impacting their overall health and wellbeing. Suggestions for small, manageable changes to daily routines, such as eating more or less of a certain kind of food or exercising at a different time of day to coincide with peak energy levels, provide Miboko users with personalized, usable data.

About Nemaura Medical, Inc.

Nemaura Medical Inc. is a medical technology company developing and commercializing non-invasive wearable diagnostic devices. The company is currently commercializing sugarBEAT® and proBEAT™. sugarBEAT®, a CE mark approved Class IIb medical device, is a non-invasive and flexible continuous glucose monitor (CGM) providing actionable insights derived from real time glucose measurements and daily glucose trend data, which may help people with diabetes and pre-diabetes to better manage, reverse, and prevent the onset of diabetes. Nemaura has submitted a PMA (Premarket Approval Application) for sugarBEAT® to the U.S. FDA. proBEAT™ combines non-invasive glucose data processed using artificial intelligence and a digital healthcare subscription service and has been launched in the U.S. as a general wellness product as part of its BEAT®diabetes program that is currently undergoing pilot studies.

Additionally, Nemaura has launched Miboko, a new metabolic health and well-being program using a non-invasive glucose sensor along with an AI mobile application that helps a user understand how certain foods and lifestyle habits can impact one’s overall metabolic health and well-being. Nemaura believes that up to half the population could benefit from a sensor and program that monitors metabolic health and well-being.

The Company sits at the intersection of the global Type 2 diabetes market that is expected to reach nearly $59 billion by 2025, the $50+ billion pre-diabetic market, and the wearable health-tech sector for weight loss and wellness applications that is estimated to reach $60 billion by 2023.

Spotlight

Envision Healthcare is one of the nation's leading medical groups, delivering care when and where it's needed most. Operating in more than 650 facilities, Envision provides care mainly in the areas of emergency medicine, hospital medicine, anesthesiology, radiology, trauma surgery and neonatology.

Spotlight

Envision Healthcare is one of the nation's leading medical groups, delivering care when and where it's needed most. Operating in more than 650 facilities, Envision provides care mainly in the areas of emergency medicine, hospital medicine, anesthesiology, radiology, trauma surgery and neonatology.

Related News

FUTURE OF HEALTHCARE

Medimap Partners with Winnipeg Regional Health Authority To Improve Emergency Room Wait Times

Medimap | November 25, 2022

Medimap is pleased to announce it has signed a strategic partnership with the Winnipeg Regional Health Authority to improve patient care and reduce emergency room wait times. The new partnership will make use of Medimap's powerful software technology and its partnerships with a large network of medical clinics in the Winnipeg area by directing Manitobans with low acuity needs to local walk-in clinics. This will help improve Manitobans' access to care by diverting patients with low acuity needs to local medical services that have the capacity to see them, thereby reducing wait times at emergency rooms across the city. "Our new partnership with the Winnipeg Regional Health Authority is a win-win for both patients and the overall healthcare system. Not only will our platform help patients with low acuity needs find the care they need, when they need it, it will also reduce wait times at emergency rooms across the city," Medimap CEO Thomas Jankowski. The partnership means the WRHA will be able to show wait time information at walk-in clinics across the Winnipeg area on hospital screens and its website. The information will allow patients to make informed decisions about where they can get timely access to care. Triage staff will also have immediate access to this information, allowing them to redirect low acuity cases to other healthcare resources. "Every month, approximately 40 percent of people who visit a Winnipeg Urgent Care Centre or emergency department could receive the health care they need, often sooner, through a family doctor or walk-in clinic," said Mike Nader, President and CEO of the Winnipeg Regional Health Authority. "By partnering with Medimap, our goal is to help Manitobans get the timely care they need while reducing the burden on our hospital system. Public-private partnerships like this will help to unlock many of the problems present in our healthcare system." Every month over 250,000 Canadians rely on Medimap as their means of finding same-day, non-urgent access to care. Its software gives clinics the ability to communicate changes in operating hours, or when they are at capacity and also provides the ability for patients to join a waitlist or book an appointment. Patients can quickly check the Medimap website before they travel to a clinic, reducing the length of time they have to wait to see a doctor. Patients can also book appointments with allied health professionals such as physiotherapists, chiropractors, optometrists, mental health services and more. About Medimap Medimap's platform is used by a network of more than 4,200 practices, pharmacies, and walk-in clinics across the country and has helped more than 12 million Canadians find the care they need when they need it. Medimap's platform also provides patients the ability to book appointments with allied health professionals such as physiotherapists, chiropractors, optometrists, mental health services, and more. Not only does this help patients receive timely care, it also helps the healthcare system divert people away from emergency rooms to primary care services that are better suited to their needs, including virtual appointments. About Winnipeg Regional Health Authority The WRHA serves residents of the city of Winnipeg, as well as the northern community of Churchill and the rural municipalities of East and West St. Paul, representing a total population of more than 750,000. The WRHA also provides healthcare support and specialty referral services to nearly half a million Manitobans who live beyond these boundaries, as well as residents of northwestern Ontario and Nunavut, who often require the services and expertise available within the WRHA.

Read More

FUTURE OF HEALTHCARE

DispatchHealth Raises More Than $330 Million to Expand Its Technology-Enabled Ecosystem of High Acuity Care in the Home

DispatchHealth | November 24, 2022

DispatchHealth, the nation's first comprehensive in-home, high acuity medical care provider announced it has raised more than $330 million in combined equity and debt financing. The equity round of $259 million was led by Optum Ventures, with participation from new investors Adams Street Partners, Blue Shield of California, among others, and continued support from existing investors Humana, Echo Health Ventures, Questa Capital and Oak HC/FT. K2 HealthVentures, Silicon Valley Bank and SVB Capital provided debt financing of $75 million, with up to an additional $75 million available for growth initiatives, bringing the total raised to more than $400 million. In the United States, $4 trillion is spent on healthcare annually and it is projected to exceed $6 trillion by 2028. With more than a third of this spend on care delivered in traditional brick-and-mortar facilities, the healthcare industry has reached a watershed moment. DispatchHealth's in-home, high acuity care model aligns health plans, health systems, at-risk provider groups and patients with complex care needs by delivering a value-based alternative to high-cost settings such as the emergency room, hospital ward or skilled nursing facility, reducing medical costs while improving clinical outcomes and patient and provider satisfaction. "For the past seven years, we have been building a comprehensive ecosystem of high acuity care in the home. Our proven approach to delivering healthcare to complex patients in their homes will continue to transform healthcare. This round of funding is a testament to what we and our passionate team members have created at DispatchHealth and the belief our partners have in our leading-edge care model." Dr. Mark Prather, Co-Founder and CEO of DispatchHealth Today, DispatchHealth provides high acuity care to complex patients across 34 states and has developed innovative relationships with health plans, provider groups, health systems, employers, senior living facilities, and home health organizations to deliver a better, more coordinated healthcare experience. DispatchHealth is also one of the largest and most experienced providers of Advanced Care, a hospital alternative, and Extended Care, a skilled nursing facility alternative. To coordinate the complex ecosystem of in-home care, DispatchHealth has created an operating system for high acuity care in the home. The proprietary technology platform uses real-time data insights to manage all aspects of the in-home care experience, including logistics, onboarding, risk stratification, care coordination and analytics that elevate the clinical practice and drive improved outcomes. DispatchHealth will use the financing to Expand its proven in-home high acuity care ecosystem in existing markets and key expansion markets; Accelerate its technology platform development to deliver consistent and scalable patient-centric care; and, Strategically grow its portfolio of in-home system of care and last mile care capabilities. "DispatchHealth is transforming the healthcare industry by improving access to outcomes-driven, high-quality, in-home care and delivering on the enhanced experience patients deserve. Optum Ventures is honored to deepen our relationship with DispatchHealth and its experienced leadership team as they continue to expand their reach of high acuity, in-home care to serve patients with complex care needs across the nation," said Laura Veroneau, Managing Partner at Optum Ventures. "DispatchHealth's comprehensive and unique ecosystem of in-home care is compelling. Adams Street is thrilled to support DispatchHealth as they expand their system of care, particularly their high acuity hospitalization substitution model. We believe DispatchHealth is positioned to catalyze important and necessary advances in the healthcare industry," said Tom Bremner, a Partner at Adams Street Partners. About DispatchHealth  DispatchHealth brings the power of the hospital to the comfort of the home. DispatchHealth is building the leading in-home system of care and offers on-demand acute care and an advanced level of medical care for people of all ages in the comfort of their own homes. DispatchHealth's emergency medicine and internal medicine trained medical teams are equipped with all the tools necessary to treat common to complex injuries and illnesses. DispatchHealth works closely with payers, providers, health systems, EMS, employer groups and others to deliver care in the home to reduce unnecessary emergency room visits, hospital stays and readmissions. Acute Care medical teams are available seven days a week, evenings and holidays and can be requested online or via a quick phone call. DispatchHealth is partnered with most major insurance companies. About Optum Ventures Optum Ventures is the independent venture fund of UnitedHealth Group. Optum Ventures invests in digital health companies that use data and insights to help improve consumers' access to healthcare services and how care is delivered and paid for, and that make the health care system more reliable and easier to navigate. About Adams Street Partners Adams Street Partners is a global private markets investment manager with investments in more than thirty countries across five continents. The firm is 100% employee-owned and has $50 billion in assets under management. Adams Street strives to generate actionable investment insights across market cycles by drawing on 50 years of private markets experience, proprietary intelligence, and trusted relationships. Adams Street has offices in Austin, Beijing, Boston, Chicago, London, Menlo Park, Munich, New York, Seoul, Singapore, and Tokyo.

Read More

FUTURE OF HEALTHCARE, MEDICAL DEVICES

Tandem Diabetes Care Successfully Acquires AMF Medical SA

Tandem Diabetes Care | January 24, 2023

On January 23, 2023, Tandem Diabetes Care, Inc., a company specializing in diabetes technology, announced that it had successfully finished acquiring AMF Medical SA, a Switzerland-based medical equipment manufacturer that created the Sigi Patch Pump. Sigi Patch Pump is a rechargeable, ergonomic patch pump intended to lower the strain of managing diabetes by utilizing pre-filled insulin cartridges. It is currently under development and is not available for retail purchase. John Sheridan, President and Chief Executive Officer of Tandem Diabetes Care, said, "AMF Medical's compelling technology aligns well with our strategic vision to include a patch pump in Tandem's portfolio of differentiated offerings." He adds, "In addition to this innovative technology, the talented AMF team joining our Tandem family shares our commitment to simplify diabetes management and brings decades of experience from the diabetes device, life sciences, and watch-making industries." (Source – Business Wire) For this transaction, Tandem Diabetes Care received legal counsel from Baker & McKenzie LLP and Bass, Berry & Sims PLC. AMF Medical relied on SVB Securities LLC as its sole financial advisor, while Homburger AG served as its exclusive legal advisor. About Tandem Diabetes Care Headquartered in San Diego (California), Tandem Diabetes Care, Inc. is a medical device company aiming to better the lives of people with diabetes through endless innovation and a novel customer experience. The company employs a fresh and user-centric approach when it comes to developing, designing, and commercializing products for those who need to use insulin. As a result, Tandem Diabetes Care is creating a positive difference by assisting in creating better outcomes for people affected by diabetes and their healthcare providers.

Read More